The Supreme Court Just Ruled for Bayer on Roundup — Here Is What It Means for Your Cancer Case
If you used Roundup and later heard the word cancer in the same sentence as your own name, you already know the worst part is not the lawsuit. The worst part is the waiting room. The biopsy. The moment someone who loves you tries to be brave and fails at it. The Supreme Court ruling that just came down is not the thing that keeps you up at night — but it may be the thing that changes whether the company whose product you sprayed for years has to answer for what happened to your body, and on what terms.
Here is what the Court held, in plain English: by a 7-2 vote, the Supreme Court ruled that Bayer — which acquired Monsanto, the original maker of Roundup, in 2018 — cannot be held liable under state law for failing to warn consumers that Roundup might cause cancer, because the Environmental Protection Agency reviewed the product under federal pesticide law and decided no cancer warning was required on the label. The Court said that when a federal regulator makes that call, state courts cannot impose a different warning duty through tort law.
That is a significant ruling. It removes the primary legal theory that drove the largest Roundup verdicts — the claim that Monsanto knew or should have known about the cancer risk and failed to put a warning on the bottle. But it does not end every Roundup case, and it does not close every door. What it does is force every plaintiff’s lawyer in the country to rebuild their case on different, harder, more expensive legal theories — and it gives Bayer enormous leverage to push settlement values down.
We are going to walk you through what this ruling means, what survives, what does not, and what to do about it. This is not a sales pitch. It is the honest analysis of a trial team that handles toxic tort and mass-tort cases and has the training to tell you the difference between a setback and a dead end.
What the Supreme Court Actually Held — and What It Did Not Hold
The decision is built on a federal statute most people have never heard of: the Federal Insecticide, Fungicide, and Rodenticide Act, known as FIFRA. FIFRA is the law that governs how pesticides are registered, labeled, and sold in the United States. Under FIFRA, the EPA reviews every pesticide label and decides what warnings must appear on it. The EPA reviewed glyphosate — the active ingredient in Roundup — and classified it as “not likely to be carcinogenic to humans.” Based on that determination, the EPA did not require a cancer warning on Roundup labels.
FIFRA contains an express preemption clause. It says that states cannot impose labeling requirements that are “in addition to or different from” what federal law requires. The Supreme Court held that this clause means what it says: when the EPA has decided no cancer warning is needed, a state tort lawsuit that would effectively require a cancer warning is preempted — blocked — by federal law.
“No State shall impose or continue in effect any requirements for labeling or packaging in addition to or different from those required under this subchapter.”
— FIFRA, 7 U.S.C. § 136v(b)
What the Court did NOT hold is equally important. The Court did not say glyphosate is safe. The Court did not say Roundup does not cause cancer. The Court did not say Bayer has no liability for anything related to Roundup. The Court addressed one specific theory — failure to warn — and held that theory is preempted when the federal regulator declined to require the warning. Every other theory of liability is a separate question the Court did not answer.
This distinction matters more than any other fact in this ruling. The failure-to-warn theory is gone, at least in its classic form. But design defect, negligent testing, fraudulent submission to the EPA, and breach of implied warranty are different legal claims that attack different conduct, and each one has to be analyzed against preemption doctrine independently.
What Legal Theories Remain for Roundup Cancer Plaintiffs
The ruling eliminates the dominant theory of liability — the one that told the jury “this company knew its product could cause cancer and did not warn you.” That theory connected the defendant’s conduct to the duty to compensate in a way a jury could feel immediately: you knew, you stayed silent, someone got sick. It was emotionally powerful and legally clean. It is now preempted.
But the law of products liability is not a single theory. It is a stack of theories, each targeting a different kind of corporate wrongdoing. Here is what remains, what it argues, and the preemption risk each one carries.
Design Defect — The Primary Path Forward
A design defect claim argues that Roundup is inherently dangerous by design — that the product itself, as formulated, is unreasonably dangerous, regardless of whether the label carried a warning. This theory attacks the product formulation, not the label. The question is not “did they warn you?” but “should this product have been designed this way at all?”
The preemption risk here is real but different. If the design defect theory would require the manufacturer to change the label — for example, by arguing that the product should have been sold only with a cancer warning — then it may face the same preemption problem. But if the theory attacks the formulation itself — that glyphosate should have been formulated differently, or that a safer alternative design existed — it may survive, because FIFRA’s preemption clause targets labeling and packaging requirements, not product formulation.
This is now the theory every plaintiff’s lawyer is pivoting toward. It is harder to prove than failure to warn because it requires expert testimony on alternative design, risk-utility balancing, and the feasibility of a safer product. But it is not preempted on its face the way failure to warn now is.
Negligence in Safety Testing and Research
This theory alleges that Monsanto and Bayer failed to conduct adequate long-term carcinogenicity studies, or ignored internal research suggesting cancer risk, or manipulated the scientific record to downplay glyphosate’s carcinogenic potential. The theory targets the company’s conduct in research and regulatory submission — what they did in the laboratory and in the papers they sent to the EPA — rather than what they wrote on the label.
The preemption analysis here turns on whether the claim would require a labeling change. If the negligence claim is about the company’s testing conduct — they should have tested more, they should have reported what they found, they should not have suppressed data — it may avoid preemption because it attacks the process, not the resulting label. This is a meaningful distinction, and it is where discovery of internal Monsanto research documents becomes the make-or-break battleground.
Fraudulent or Negligent Misrepresentation to the EPA
If discovery reveals that Monsanto submitted misleading, incomplete, or cherry-picked data to the EPA during the registration process — if the company told the regulator something different from what its own internal research showed — that is a theory that attacks the integrity of the regulatory process rather than the resulting label. The argument is that the EPA’s no-warning determination was built on a false foundation supplied by the company itself.
This theory is powerful because it turns the preemption ruling on its head: the company cannot benefit from a regulatory determination that it obtained through deception. But proving it requires access to internal Monsanto documents — the studies, the emails, the communications between scientists and executives — that may be locked behind protective orders from prior litigation or may require aggressive discovery to surface.
Breach of Implied Warranty
A breach of implied warranty claim argues that Roundup was not fit for its ordinary use — that a consumer buying a weedkiller should not be exposed to a cancer risk from normal use. This theory is partially preempted to the extent it depends on the adequacy of warnings, but it may survive to the extent it challenges the product’s fitness independent of labeling.
How This Ruling Affects Existing Roundup Cases
If you already have a Roundup case filed, or if you are part of the consolidated federal litigation — the multidistrict litigation docket in the Northern District of California — the ruling does not automatically dismiss your case. What it does is give Bayer a powerful new motion to dismiss or for summary judgment on your failure-to-warn claims.
Your lawyer will need to evaluate whether your complaint pleads alternative theories that survive preemption, whether your specific facts support those theories, and whether the ruling applies retroactively to your case or only prospectively. The procedural posture of your case matters: a case still at the pleading stage is in a different position than one that has already gone through discovery or is approaching trial.
If you were offered a settlement before this ruling came down, that offer may be retracted, reduced, or renegotiated. Bayer now holds a stronger litigation position because the primary theory that drove the largest verdicts has been struck down. Settlement leverage has shifted meaningfully toward the company.
If your case has already been tried and you won a verdict based on failure to warn, the ruling may give Bayer grounds for post-trial motions or appeal, depending on the procedural status of your case. A verdict that has already been affirmed on appeal is in a different posture than one still under direct appellate review.
The Scientific Dispute at the Heart of Every Roundup Case
The Supreme Court’s ruling is a legal decision about preemption. It is not a scientific ruling about whether glyphosate causes cancer. The scientific question — does Roundup cause non-Hodgkin’s lymphoma? — remains contested, and it is the question every surviving Roundup case still has to answer.
Two major regulatory and scientific bodies reached opposite conclusions on glyphosate’s carcinogenicity. The EPA classified glyphosate as “not likely to be carcinogenic to humans.” The International Agency for Research on Cancer — IARC, part of the World Health Organization — classified glyphosate as “probably carcinogenic to humans” in 2015. These are not minor institutions, and they are not close together. One says probably yes. The other says probably no. That gap is the space every Roundup case lives in.
For a plaintiff, the IARC classification is the scientific anchor. For the defense, the EPA determination is both the scientific anchor and now the legal shield. The Supreme Court’s ruling makes the EPA’s determination legally controlling for failure-to-warn purposes — but it does not make the EPA’s science scientifically controlling for design defect, negligent testing, or fraud theories, where the question is what the company knew, what it tested, and what it told the regulator.
The Medicine — Non-Hodgkin’s Lymphoma and What It Does to a Family
Non-Hodgkin’s lymphoma is a cancer of the lymphatic system — the body’s network of nodes and vessels that is part of the immune system. It begins in white blood cells called lymphocytes, which mutate and grow uncontrollably. The diagnosis changes a family’s life on the day it is spoken.
The symptoms that lead to diagnosis are often quiet at first: a swollen lymph node in the neck, armpit, or groin that does not go away. Fatigue. Unexplained weight loss. Night sweats that soak the sheets. A fever that comes and goes without explanation. By the time these symptoms drive someone to the doctor, the cancer may already be advanced.
The diagnostics run from blood tests and imaging — CT scans, PET scans — to a lymph node biopsy, where a surgeon removes a swollen node and a pathologist examines it under a microscope to confirm the diagnosis and identify the specific subtype. There are more than 70 subtypes of non-Hodgkin’s lymphoma, and the subtype determines the treatment and the prognosis.
Treatment can include chemotherapy regimens that run for months, immunotherapy drugs that harness the immune system to attack the cancer, radiation therapy targeted at affected lymph node regions, and in some cases stem cell transplants — a grueling process where the patient’s own blood-forming cells are harvested, high-dose chemotherapy is given to wipe out the bone marrow, and the harvested cells are returned to rebuild the immune system from scratch. Each of these treatments carries its own risks: infection, organ damage, secondary cancers, infertility, and years of surveillance for recurrence.
The cost is staggering. A single course of treatment for non-Hodgkin’s lymphoma can run into the hundreds of thousands of dollars. A stem cell transplant can cost more. And the surveillance does not end when treatment does — follow-up scans, blood tests, and oncologist visits continue for years, because non-Hodgkin’s lymphoma can recur.
The proof problem the defense exploits in every surviving Roundup case is specific causation: even if you can show that glyphosate is capable of causing non-Hodgkin’s lymphoma in general, you have to show that THIS plaintiff’s cancer came from glyphosate exposure and not from something else. Non-Hodgkin’s lymphoma has many known and suspected causes — age, immune system suppression, certain infections, family history, other chemical exposures. The defense will argue that your cancer was idiopathic — meaning it came from no identifiable cause — or that it came from something other than Roundup.
The counter is dose reconstruction: how much Roundup did you use, how often, for how many years, and what was your cumulative exposure? This is where plaintiff-specific exposure records — purchase receipts, employment history if you used it professionally, testimony from family members about your usage patterns — become the foundation of the case. A board-certified toxicologist then has to connect that dose to your specific cancer, under the applicable jurisdiction’s standard for expert testimony.
The Defendant — Bayer AG and Monsanto Company
Bayer AG is a German pharmaceutical and life sciences multinational. In 2018, Bayer acquired Monsanto Company for approximately $63 billion — and with that acquisition, Bayer inherited the entire Roundup product line and the litigation that came with it. Monsanto, now a Bayer subsidiary, was the original manufacturer, designer, and marketer of Roundup. It was Monsanto that submitted glyphosate for EPA registration, conducted or controlled the safety research underlying the EPA’s no-warning determination, and sold the product for decades.
The corporate structure matters because liability flows differently through different entities. Monsanto is the entity that designed the product, ran the studies, and made the submissions to the EPA. Bayer is the deep-pocket parent that assumed successor liability when it acquired Monsanto. In practice, both are named as defendants, but the relationship between them — and the insurance and indemnity structures behind them — is a question for discovery.
Bayer is what we call a balance-sheet defendant. It is a global pharmaceutical giant with resources that dwarf any individual insurance policy. Recovery against Bayer is not gated by a finite insurance tower the way it is against a trucking company or a small nursing home operator. The company itself is the source of recovery — which means the fight is not about whether there is money to pay a verdict, but about whether you can prove liability under the surviving legal theories.
The Roundup litigation is consolidated in a federal multidistrict litigation — MDL-2741, In re: Roundup Products Liability Litigation, in the Northern District of California, before Judge Vince Chhabria. As of mid-2026, the MDL docket had thousands of cases. The MDL centralizes pretrial proceedings — discovery, expert challenges, bellwether trials — but each plaintiff retains an individual case. Joining the MDL does not merge your case into a class action. You keep your own claim, your own facts, your own lawyer.
The Evidence Clock — What Records Exist and How Fast They Can Disappear
Every surviving Roundup case depends on evidence that exists on a clock. Some of it has already been produced in prior litigation. Some of it is locked behind protective orders. Some of it has never been seen by plaintiffs. And some of it is plaintiff-specific — your records, your exposure history — that you or your family hold and that must be preserved immediately.
Internal Monsanto and Bayer research documents on glyphosate carcinogenicity. These are the documents that establish what the company knew about cancer risk and when. Many were produced in the MDL discovery process, but some remain under protective orders or confidentiality designations. The internal research file is the spine of every negligent-testing and fraud theory — it is where you find the studies the company ran but never published, the memos where scientists raised concerns that were overruled by executives, and the data that was either submitted to the EPA in full or selectively curated. These documents survive in litigation archives, but access depends on the protective order regime in your specific case.
EPA submission files and regulatory correspondence. These are the records that show what Monsanto told the EPA during the registration process — the studies it submitted, the data it included, the data it omitted, and the correspondence between the company and the agency. Some of these are already public from prior litigation; others require targeted Freedom of Information Act requests to the EPA for specific submission packages. The gap between what the company told the EPA and what its own internal research showed is the foundation of any fraudulent-submission theory.
Internal emails and communications about cancer research and the IARC classification. When IARC classified glyphosate as “probably carcinogenic to humans” in 2015, the internal reaction at Monsanto — the emails, the strategy memos, the communications about how to challenge or discredit the IARC finding — is evidence of corporate knowledge and corporate conduct. Many of these documents were produced in the MDL, but their accessibility depends on the protective order and confidentiality designations from earlier proceedings.
Scientific study raw data and ghostwriting evidence. One of the most powerful categories of evidence in the Roundup litigation is proof that Monsanto influenced, funded, or ghostwrote supposedly independent scientific literature downplaying the cancer risk. If internal documents show that the company planted favorable studies in the scientific record and presented them as independent research, that supports both the negligence-in-testing theory and the fraud theory. These documents have been produced in prior litigation but may require challenges to existing protective orders to access.
Your own exposure and medical records. These are the records that prove YOUR specific case — how long you used Roundup, how often, in what quantities, and the temporal relationship between your exposure and your cancer diagnosis. Purchase receipts, employment records if you used Roundup professionally, testimony from family members, and your complete medical history from your treating oncologist. Medical records retention varies by provider — some keep records for seven years, some for ten, some longer. If you have already been diagnosed, your oncology records are being created right now and will continue to accumulate through treatment. Do not wait to begin assembling your exposure history — memory fades, receipts are discarded, and people who could testify about your usage patterns move or pass away.
The preservation principle is simple: the day you contact a lawyer is the day the clock starts working for you instead of against you. A preservation letter freezes the corporate documents that can still be reached. Your own records — medical, employment, purchase — need to be gathered before they are lost.
What Your Case May Be Worth After This Ruling
We are going to be honest with you, because honesty is the only thing that actually helps in this moment.
The failure-to-warn theory was the engine that drove the largest Roundup verdicts. Verdicts in prior Roundup cases reached into the tens of millions of dollars — but those verdicts were built on the theory that the jury has now been told it cannot consider. Some of those verdicts were reduced on appeal. Some were reversed. The record was always mixed, and it is now narrower.
The Supreme Court’s ruling does not cap or eliminate damages as a category. It eliminates the primary liability theory that connected the defendant’s conduct to the duty to compensate. The damages categories — past and future medical treatment, lost wages, diminished earning capacity, pain and suffering, emotional distress, loss of quality of life, and in wrongful death cases the family’s losses — all still exist. What changed is the bridge between the defendant’s conduct and those damages. That bridge now has to be built on alternative theories, and the bridge is narrower and harder to cross.
For cases that relied primarily or exclusively on failure to warn, the ruling may mean dismissal or sharply reduced settlement value. For plaintiffs with strong exposure histories — long-term, heavy Roundup use — confirmed non-Hodgkin’s lymphoma diagnoses, and viable alternative theories, recovery may still be possible. But the path is harder, more expensive to litigate, and less certain.
Individual case value depends on:
– The specific state’s product liability framework and its treatment of design defect claims for toxic products
– The strength of alternative theories available on your specific facts
– Exposure duration and intensity — how much, how often, for how many years
– Cancer type, subtype, and prognosis
– The admissibility of expert causation testimony under your jurisdiction’s standard for scientific evidence
– Whether your state has damage caps that limit non-economic or punitive recovery
– Your age, earning capacity, and family circumstances
We cannot tell you what your case is worth without evaluating these factors. What we can tell you is that the range has shifted. Cases that might have settled for significant amounts before this ruling may now face dismissal motions, reduced settlement offers, or the need to invest substantially more in expert testimony and discovery to survive.
Past results depend on the facts of each case and do not guarantee future outcomes.
The Insurance and Corporate Playbook — What Bayer Will Do Now
Bayer’s litigation strategy after this ruling is predictable because it follows the playbook every pharmaceutical and chemical defendant runs when it gets a favorable appellate ruling. Here are the moves you should expect — and what can be done about each one.
Play 1: Move to dismiss every failure-to-warn claim. Bayer will file motions to dismiss or for summary judgment in every pending Roundup case, arguing that failure-to-warn claims are preempted under the Supreme Court’s ruling. The counter is that your complaint must plead alternative theories — design defect, negligent testing, fraud — that are not preempted. If your complaint relied solely on failure to warn, it may need to be amended. The time to do that is now, before the motion is filed, not after.
Play 2: Argue that the remaining theories are preempted too. Bayer will not stop at failure to warn. It will argue that design defect claims are implicitly preempted because they would require labeling changes, or that negligent-testing claims are really just failure-to-warn claims in disguise. The counter is careful pleading that distinguishes the conduct being attacked — the formulation, the testing, the regulatory submission — from the label itself. The more your theory targets what the company did in the lab and in its communications with the EPA, and the less it targets what was written on the bottle, the stronger your preemption defense.
Play 3: Use the ruling to pressure plaintiffs into accepting reduced settlements. Bayer’s settlement calculus just shifted. Before the ruling, the threat of a large failure-to-warn verdict drove settlement value. Now, Bayer can point to the ruling and say: your primary theory is dead, your alternative theories are expensive to prove, and you may lose on preemption too. The counter is that the alternative theories, while harder, are not dead — and a case with strong exposure history and confirmed cancer still carries risk for the company, especially if discovery produces internal documents showing corporate knowledge of cancer risk.
Play 4: Attack expert causation testimony. With failure to warn gone, the make-or-break battleground shifts to specific causation — can your expert prove that YOUR cancer came from glyphosate? Bayer will challenge your expert’s methodology under the applicable standard for scientific evidence in your jurisdiction. The counter is a board-certified toxicologist and oncologist who can reconstruct your dose, apply the dose-response literature, and rule out alternative causes through differential diagnosis. This is where the case is won or lost now.
Play 5: Validate the EPA’s process as a shield against punitive damages. Bayer will argue that it complied with federal regulatory requirements, that the EPA reviewed the science and decided no warning was needed, and that punishing the company for relying on the regulatory process is unfair. The counter, on the fraud theory, is that the regulatory process was corrupted by the company’s own misrepresentations — and a regulator deceived into issuing a favorable determination is not a shield, it is a sword.
The Proof Story — How a Surviving Roundup Case Is Built
Here is how a Roundup case that survives this ruling is actually constructed, from the day you call to the day a number is put on the table.
The preservation demand goes out first — to Bayer, to Monsanto, to any third-party data vendors holding internal research or regulatory submission records — freezing the corporate documents before they can be lost or destroyed. Your own records are gathered simultaneously: medical records from every treating oncologist, every hospital, every radiation facility; employment records if you used Roundup professionally; purchase records or testimony about your personal use; and statements from family members, coworkers, or neighbors who can describe your usage patterns.
The exposure reconstruction comes next. A toxicologist builds your dose history — how much glyphosate you were exposed to, over how many years, through what pathway (skin contact, inhalation, ingestion). This is not a guess. It is a calculation built from your usage history, the product concentrations you used, the frequency and duration of application, and the established absorption and pharmacokinetic data for glyphosate.
The specific causation analysis follows. Your oncologist and an expert toxicologist work together to connect your dose to your cancer. The defense will argue your cancer was idiopathic — that it came from nowhere identifiable, or from something other than Roundup. The counter is differential diagnosis: systematically ruling out other known causes of non-Hodgkin’s lymphoma and showing that your glyphosate exposure is the most likely explanation.
The corporate conduct discovery runs in parallel. Internal Monsanto research documents, EPA submission files, internal emails about the IARC classification, and any evidence of ghostwriting or scientific manipulation — these are the documents that power the design defect, negligent testing, and fraud theories. If the discovery produces evidence that the company’s own scientists raised cancer concerns that were overruled by executives, or that data submitted to the EPA was selectively curated, that is the foundation of both liability and punitive damages.
The expert challenges come next. Bayer will move to exclude your causation experts under the standard governing scientific evidence in your jurisdiction. Your experts’ qualifications, methodology, and the literature they rely on will be scrutinized. This is now the single most important motion in any surviving Roundup case — if your experts are excluded, the case is over.
If the experts survive, the case moves toward trial or settlement. The number at the end is built from all of it — your medical costs, your lost earnings, your pain and suffering, your family’s losses, and the leverage of what the jury will hear about what the company knew and when.
What to Do in the First 72 Hours After This Ruling
If you have an existing Roundup case, call your current lawyer. Ask them specifically: what theories does my complaint plead? Does it rely on failure to warn? If so, what is the plan to amend? What alternative theories are available on my facts? What is the preemption risk for each? This is not a question for next month. Motions to dismiss will be filed quickly.
If you were considering filing a Roundup case and have not yet, understand that the landscape has changed. Your case will need to be built on alternative theories from the start, which means more expert work, more discovery, and more upfront investment by your legal team. But if you have a strong exposure history and a confirmed cancer diagnosis, your case may still be viable. The evaluation has to be individual — there is no blanket answer.
If you have lost a family member to non-Hodgkin’s lymphoma and believe Roundup exposure was the cause, wrongful death claims follow the same legal framework but add their own procedural requirements — the appointment of a personal representative, the beneficiary hierarchy under your state’s wrongful death statute, and the survival action for the decedent’s pre-death pain and suffering.
Gather your records now. Every purchase receipt, every employment record showing Roundup use, every medical record from your cancer diagnosis forward. Memory fades. Receipts are thrown away. People who could describe your usage patterns move on. The evidence of your exposure is perishable, and it is yours to preserve.
Do not sign anything from Bayer, Monsanto, or any claims administrator without having it reviewed. If you receive a settlement offer — especially one that arrives in the wake of this ruling — have a lawyer evaluate whether it reflects the true value of your case under the surviving theories, not just the discounted value the company now thinks it can get away with.
Do not give a recorded statement to any insurance adjuster or claims representative. What you say can and will be used to minimize your claim — and with the legal landscape shifted, the defense has more incentive than ever to find inconsistencies in your exposure history.
The Statute of Limitations — How Long You Have
Every state has its own statute of limitations for product liability and personal injury claims, and the deadlines vary — typically ranging from two to six years from the date the claim accrued. For toxic exposure cases like Roundup, many states apply a discovery rule: the clock does not start on the date you were exposed to the product. It starts on the date you knew or should have known that your injury was caused by that exposure.
For most Roundup plaintiffs, that means the clock likely started when you were diagnosed with non-Hodgkin’s lymphoma, or when you first learned that glyphosate exposure may have caused your cancer — not when you last sprayed Roundup in your yard.
But this is not uniform. Some states have statutes of repose that impose an outer deadline regardless of when you discovered the injury. Some states calculate the discovery rule differently. Some have specific rules for toxic tort cases. And the Supreme Court’s ruling may itself affect accrual analysis in some jurisdictions — if the legal landscape has just changed, does that restart any clock? These are questions that require a lawyer licensed in your state to answer.
What we can tell you with certainty is this: if you think you have a claim, the safest assumption is that the clock is running. Every state has a deadline, and once it passes, the case is over — no matter how strong your facts are. The deadline does not care about the Supreme Court ruling, about your treatment schedule, or about whether you were still gathering your records. It runs, and when it stops, the door is closed.
Why This Firm — and What the First Call Looks Like
Ralph Manginello has spent 27-plus years licensed in courtrooms, including federal court. He was a journalist before he was a lawyer, which means he was trained to find the document that changes the story — the memo nobody wanted found, the study that was buried, the email that says what the polished regulatory submission does not. That instinct is exactly what a post-ruling Roundup case demands, because the surviving theories all turn on what the company knew and what it did with what it knew.
Lupe Peña spent years inside a national insurance-defense firm — the rooms where claims like yours are priced, where adjusters and their software decide how to deny, delay, and devalue people exactly like you. He knows how the other side values a claim when the primary theory has been struck down, because he sat in the seat that does the devaluing. He is fluent in Spanish and conducts full consultations in Spanish without an interpreter. We serve your family fully in either language.
We work on contingency. That means we do not get paid unless we win your case. The fee is 33.33 percent if the case resolves before trial and 40 percent if it goes to trial. The first consultation is free. You can call us at 1-888-ATTY-911, 24 hours a day, seven days a week, and you will speak to a live person — not an answering service.
When you call, here is what happens. We listen. We ask about your Roundup use — how long, how often, what kind. We ask about your diagnosis — when, what subtype, what treatment. We ask about your medical history and your family. We tell you honestly whether we think you have a case that can survive this ruling, and if we do not think we are the right fit for you, we will tell you that too. We do not promise outcomes. We promise an honest evaluation and a fight if the facts support one.
Hablamos Español.
Frequently Asked Questions
Can I still sue Bayer if I used Roundup and got cancer?
Yes, but your case must be built on legal theories that survived the Supreme Court’s ruling. The failure-to-warn theory — the claim that Monsanto should have put a cancer warning on the label — is now preempted by federal law when the EPA did not require that warning. But design defect, negligent testing, and fraudulent submission to the EPA are different theories that may still be viable depending on your facts. Each case has to be evaluated individually.
I already have a Roundup lawsuit filed. What happens to my case now?
Your case is not automatically dismissed, but your lawyer will need to evaluate whether your complaint pleads theories that survive preemption. If your case relies solely on failure to warn, Bayer will likely file a motion to dismiss. Your lawyer may need to amend your complaint to add alternative theories. Call your current attorney and ask specifically what theories your case pleads and what the plan is for responding to the ruling.
Does this ruling mean Roundup is safe?
No. The Supreme Court’s ruling is a legal decision about preemption — whether federal pesticide law overrides state tort law on warning labels. It is not a scientific ruling about whether glyphosate causes cancer. The scientific dispute remains unresolved. The EPA says glyphosate is “not likely to be carcinogenic to humans.” IARC, the World Health Organization’s cancer research arm, says it is “probably carcinogenic to humans.” Those contradictory conclusions are the gap every surviving Roundup case has to address.
What is FIFRA preemption and why does it matter?
FIFRA is the Federal Insecticide, Fungicide, and Rodenticide Act, the federal law that governs pesticide registration and labeling in the United States. It contains a provision that says states cannot impose labeling requirements different from what federal law requires. The Supreme Court held that when the EPA decides no cancer warning is needed, a state tort lawsuit seeking to impose a cancer warning duty is the kind of “requirement” that FIFRA preempts. This matters because it removes the strongest, most intuitive theory of liability from every Roundup case.
How much is my Roundup case worth after this ruling?
Case value depends on your specific facts — your exposure history, your cancer type and prognosis, your state’s product liability law, and the strength of alternative legal theories. The ruling has reduced settlement leverage across the board because the theory that drove the largest verdicts is now preempted. Cases with strong exposure histories and viable alternative theories may still have significant value. Cases that relied solely on failure to warn may face dismissal. An honest evaluation requires a lawyer to review your specific facts.
Is the Roundup class action still active?
The Roundup litigation is not a class action — it is a multidistrict litigation, or MDL, which consolidates pretrial proceedings but preserves each plaintiff’s individual case. The MDL remains active. The Supreme Court’s ruling affects the legal theories available in those individual cases but does not dissolve the MDL itself.
What if a family member died from cancer after using Roundup?
Wrongful death claims follow the same legal framework as personal injury claims but add procedural requirements — a personal representative must be appointed, and recovery is limited to the beneficiaries defined by your state’s wrongful death statute. The ruling affects wrongful death cases the same way it affects injury cases: failure to warn is preempted, but alternative theories may survive. The statute of limitations for wrongful death is typically shorter than for personal injury and runs from the date of death, so time is a critical factor.
Should I accept a settlement offer I already received?
Do not accept or sign anything without having it reviewed by a lawyer who understands the post-ruling landscape. If you received an offer before this ruling came down, the offer may no longer reflect the true posture of your case. Bayer now has incentive to push settlement values down. A lawyer can evaluate whether the offer accounts for surviving theories, your specific exposure history, and the full range of damages available under your state’s law.
How long do I have to file a Roundup cancer lawsuit?
The statute of limitations varies by state — typically two to six years. For toxic exposure cases, many states apply a discovery rule, meaning the clock starts when you knew or should have known your cancer was caused by glyphosate exposure, not when you last used the product. Some states have statutes of repose that impose an outer deadline regardless of discovery. You need a lawyer licensed in your state to tell you the exact deadline that applies to your case. The safest assumption is that the clock is running.
What evidence do I need for a Roundup case?
You need proof of your exposure — how long you used Roundup, how often, in what quantities. This can come from purchase receipts, employment records if you used it professionally, and testimony from family members or coworkers. You need your complete medical records — diagnosis, treatment, pathology reports, oncologist notes. And the corporate evidence — internal Monsanto research, EPA submission files, internal communications about cancer risk — comes through discovery in the litigation itself. Start gathering your personal records now.
Will the Supreme Court ruling be overturned?
The ruling is a 7-2 decision of the United States Supreme Court. It is the law of the land. Overturning a Supreme Court ruling requires either a subsequent Supreme Court decision that revisits the question — which is rare and typically requires a change in the Court’s composition or a significant change in circumstances — or a constitutional amendment. Congress could also amend FIFRA to change the preemption provision, which is a political question outside the courts. For the foreseeable future, this ruling stands.
Can I still join the Roundup MDL if I have not filed yet?
The MDL remains active and accepts new filings, but the legal theories available to new plaintiffs are the same as those available to existing plaintiffs — meaning failure to warn is preempted and alternative theories must be pleaded from the start. If you are considering filing, contact a lawyer who can evaluate whether your facts support a viable claim under the surviving theories before you commit to litigation.
If You Used Roundup and Got Cancer — The Next Step Is Yours
The Supreme Court changed the legal landscape. It did not change what happened to you. If you sprayed Roundup for years and a doctor later said the word lymphoma in a room that went quiet, the ruling does not erase that. It makes the legal fight harder — but harder is not the same as impossible, and the theories that remain are the ones that ask the deepest questions about what this company knew, what it tested, and what it told the regulator who was supposed to be protecting you.
The call is free. The evaluation is honest. We will tell you whether your case can survive this ruling, and if it can, we will tell you how. If it cannot, we will tell you that too — because you deserve the truth, not a sales pitch built on a ruling that just took the strongest theory off the table.
Call 1-888-ATTY-911. Free consultation. No fee unless we win your case. Hablamos Español.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Contacting the firm is free and confidential.